Ipsen SA has discontinued development of its steroid sulfatase inhibitor, Irosustat, as a monotherapy for the treatment of hormone-dependent cancers. Instead it will explore development of the drug in combination with other hormonal therapies. ---Subscribe to MedNous to access this article--- Company News Research & University News
